Deferred Tax Assets, Operating Loss Carryforwards in USD of Can-Fite BioPharma Ltd. from Q4 2018 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Can-Fite BioPharma Ltd. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and change rate from Q4 2018 to Q4 2024.
  • Can-Fite BioPharma Ltd. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Dec 2024 was $27M, a 5.44% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Can-Fite BioPharma Ltd. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2024 $27M +$1.39M +5.44% 31 Dec 2024 20-F 14 Apr 2025
Q4 2023 $25.6M +$469K +1.87% 31 Dec 2023 20-F 14 Apr 2025
Q4 2022 $25.1M -$1.21M -4.6% 31 Dec 2022 20-F 28 Mar 2024
Q4 2021 $26.3M -$5.96M -18.5% 31 Dec 2021 20-F 30 Mar 2023
Q4 2020 $32.3M +$5.02M +18.4% 31 Dec 2020 20-F 24 Mar 2022
Q4 2019 $27.3M +$4.36M +19% 31 Dec 2019 20-F 25 Mar 2021
Q4 2018 $22.9M 31 Dec 2018 6-K 01 Jun 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.